stockrowGlaukos Corporation
GKOS Healthcare Medical Devices
Glaukos Corporation’s revenue for fiscal 2025 (year ended December 2025) was $507.4 million, up 32.3% from fiscal 2024.
- Revenue
- +58.0%
- EPS
- +110.7%
- Free cash flow
- +411.2%
- Total debt
- −2.25%
Quarter to September 2026, against a year earlier
Follow GKOS
Alert me
Glaukos Corporation (GKOS) Return on equity
Glaukos Corporation's return on equity over the twelve months to 30 September 2026 was −22.8%, up 3.5 percentage points from fiscal 2025 (−26.4%). Over the past ten years it has ranged from −27.2% (fiscal 2023) to 113.3% (fiscal 2015); the current reading is higher than 18% of that period. That is below the Medical Devices industry median of −10.4% and above the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | −26.4% | (2.55) |
| FY2024 | −23.8% | 3.33 |
| FY2023 | −27.2% | (9.40) |
| FY2022 | −17.8% | (9.85) |
| FY2021 | −7.91% | 10.04 |
| FY2020 | −18.0% | (21.59) |
| FY2019 | 3.64% | 11.94 |
| FY2018 | −8.30% | (8.23) |
| FY2017 | −0.07% | (4.33) |
| FY2016 | 4.26% | (109.08) |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| PODD Insulet Corporation compare | 28.9% |
| BIO.B Bio-Rad Laboratories, Inc. compare | 14.3% |
| BIO Bio-Rad Laboratories, Inc. compare | 14.3% |
| GMED Globus Medical, Inc. compare | 12.1% |
| PEN Penumbra, Inc. compare | 10.7% |
| ZBH Zimmer Biomet Holdings, Inc. compare | 6.02% |
| SNN Smith & Nephew SNATS, Inc. compare | 0.00% |
| BRKR Bruker Corporation compare | −7.04% |
| GKOS Glaukos Corporation | −22.8% |
| Medical Devices industry median | −10.4% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on GKOS
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement